TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04276194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy
Description: Undergo intensity modulated proton therapy
Study: NCT01102231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERBITUX
Description: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66 Gy (2 Gy by fraction, 5 fractions by week)
Study: NCT03303287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School health education
Description: School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
Study: NCT01245764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02679196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KA2237
Description: PI3 Kinase p110β/δ inhibitor
Study: NCT04717778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk
Description: They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
Study: NCT01095796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
Study: NCT04276194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03170427

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory level
Description: Sensory levels are checked using touch with alcohol puffs

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sensory level
Description: Sensory levels are checked using touch with alcohol puffs
Study: NCT00725751

Intervention type: BIOLOGICAL
Intervention: Pegylated interferon alfa-2b (PegIFN-2b)
Description: PegIFN-2b administered according to European labeling.

Intervention type: BIOLOGICAL
Intervention: Pegylated interferon alfa-2b (PegIFN-2b)
Description: PegIFN-2b administered according to European labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered according to European labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered according to European labeling.
Study: NCT02914093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT
Description: Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
Study: NCT01093664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE AD02
Description: s.c. injection
Study: NCT01660399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boanmycin
Description: Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, intravenous infusion, day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, intravenous infusion, day 1.
Study: NCT03679052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
Study: NCT01484613

Intervention type: DEVICE
Intervention: quadripolar LV lead (Quartet)
Description: All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
Study: NCT00537927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic correction of hernia with mesh
Description: Correction of hernia with mesh and fixation of mesh using one of the arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic correction of hernia with mesh
Description: Correction of hernia with mesh and fixation of mesh using one of the arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic correction of hernia with mesh
Description: Correction of hernia with mesh and fixation of mesh using one of the arms.
Study: NCT02733315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Conversation Map Program
Description: The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants.
Study: NCT03688282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable vibration belt
Description: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham, wearing belt
Description: The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
Study: NCT02583386

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Free From Falls fall prevention program
Description: Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Free From Falls fall prevention program
Description: Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Fall Detector
Description: 30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Fall Detector
Description: 30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
Study: NCT04236570

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermode(hot plate) and cold water bath
Description: Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS(transcutaneous electrical nerve stimulation)
Description: TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
Study: NCT04214925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.

Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi
Description: Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
Study: NCT01095796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild Placebo
Description: Placebo to match Stribild STR administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla Placebo
Description: Placebo to match Atripla tablet administered orally once daily prior to bedtime
Study: NCT02752230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux en Y gastric bypass
Description: Laparoscopic Roux en Y gastric bypass
Study: NCT02294422

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBP
Description: the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOR

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aneroid manometer
Description: The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aneroid manometer
Description: The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
Study: NCT02278081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: the lansoprazole will be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the lansoprazole placebo will be taken orally.
Study: NCT04021459

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples
Description: 3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method.
Study: NCT04572581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Breast Milk
Description: Donor breast milk will be given to the newborn if supplementation is required
Study: NCT03015025

Intervention type: GENETIC
Intervention: Acenocoumarol
Description: A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
Study: NCT03820726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Bid
Study: NCT00345540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV-002
Description: 60 mg / mL / day / 20-23 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 following IV bolus administration of NOV-002
Study: NCT01011218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBT-I
Description: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BBT-I
Description: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control behavioral intervention is a sleep hygiene handout completed by participant.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control behavioral intervention is a sleep hygiene handout completed by participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
Study: NCT02233907

Intervention type: DRUG
Intervention: Ventilat® - metered dose inhaler
Study: NCT01539811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision and drainage of diabetic foot infection
Description: Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision and drainage of diabetic foot infection
Description: Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short course antibiotics
Description: Short course (\<2 weeks) of antibiotics will be prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long course antibiotics
Description: Long course (\>2 weeks) of antibiotics will be prescribed
Study: NCT03424317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sodium intake reduction
Description: Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
Study: NCT03010722

Intervention type: DRUG
Intervention: Regorafenib
Description: Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets.
Study: NCT03384108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-13C-Glutamine
Description: Intravenous infusion of 5-13C-Glutamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration of bone marrow aspirate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration of bone marrow aspirate
Study: NCT03581175

Intervention type: PROCEDURE
Intervention: Colonoscopy

Intervention type: PROCEDURE
Intervention: Colonoscopy

Intervention type: DRUG
Intervention: Bowel cleansing regimen

Intervention type: DRUG
Intervention: Bowel cleansing regimen
Study: NCT03186768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap on a rope hall pass intervention
Description: School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
Study: NCT01381367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23 pneumococcal vaccine (Pneumovax®)
Description: The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline, 0.5ml given subcutaneously
Study: NCT04203589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Explorer Baby Early Intervention Program
Description: Centered based intervention, once or twice a month, 6 months follow up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: Centered based intervention, once or twice a month, 6 months follow up
Study: NCT01405183

Intervention type: OTHER
Intervention: Hepatitis C testing
Description: Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype

Intervention type: OTHER
Intervention: Hepatitis C testing
Description: Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
Study: NCT01322256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy
Description: Bone scintigraphy of the affected area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukoscan
Description: Scintigraphy with labeled neutrophils

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET / CT
Description: PET / CT of the affected area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone biopsy
Description: A bone biopsy is performed during pre-inclusion work up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bloodwork
Description: CRP and procalcitonin are measured in the pre-inclusion work up.
Study: NCT00149786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy
Description: Family therapy will be given for a total of 24 hours over the course of 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ego-Oriented Individual Psychotherapy
Description: Individual therapy will be given for a total of 24 hours over the course of 12 months.
Study: NCT03756116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epinephrine sprayed on the papilla
Description: Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
Study: NCT02644837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Record number of manipulations
Description: The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
Study: NCT03756116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline sprayed on the papilla
Description: Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
Study: NCT02971709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shade Sail
Description: Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
Study: NCT02492243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILR implantation
Study: NCT02644837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of device related trauma
Description: Observation and assessment of any trauma caused by the insertion of the first device used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of device related trauma
Description: Observation and assessment of any trauma caused by the insertion of the first device used
Study: NCT03342456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate Enteric-Coated Capsules
Description: group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Capsules
Description: group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole Enteric-Coated Tablets
Description: group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole Enteric-Coated Tablets
Description: group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone Tablets
Description: group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
Study: NCT01369043

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E and Vitamin C
Description: Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
Study: NCT03584906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DGG Harvesting approach
Description: An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
Study: NCT02920385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once daily alone or together with levothyroxine or Placebo
Study: NCT03584906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ET harvesting approach
Description: A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
Study: NCT03342456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone Tablets
Description: group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Tablets
Description: group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Citrate Tablets
Description: group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
Study: NCT02920385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration once daily alone or together with levothyroxine or semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral administration alone or together with SNAC or oral semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration once daily together with semaglutide
Study: NCT03834441

Intervention type: OTHER
Group type: OTHER
Intervention: Oral HRSN screening
Description: Verbal screening delivered by an RA